Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|May 13, 2020

How Children and Adolescents Are Responding to the Pandemic

Author(s)Leela Magavi, MD

A child/adolescent and adult psychiatrist answers three key questions regarding youth and COVID-19.

A child/adolescent and adult psychiatrist will answers three questions regarding youth and COVID-19. Leela Magavi, MD, is Regional Director of Community Psychiatry, in Newport Beach, CA.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

long covid

Phase 2 Trial of Bezisterim for Neurological Symptoms of Long COVID: Treatment Phase Completed

August 31st 2026

teen social media

An Update on the Harms of Social Media on Teen Mental Health: Meta Settles for $18 Billion

August 28th 2026

The Art Wave/Adobe Stock

The 5 Faces of Bipolar Depression: A Case-Based Reflection

ByHameed Younis, MD

August 26th 2026

smoking cessation

Update on Varenicline for Smoking Cessation in Patients With Bipolar Disorder

ByDavid N. Osser, MD

August 18th 2026

stuttering

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Ethics and AI Use in Medical Practice: American College of Physicians Releases Position Statement

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction